0 236

Cited 22 times in

Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김호근-
dc.date.accessioned2020-07-02T16:41:03Z-
dc.date.available2020-07-02T16:41:03Z-
dc.date.issued1998-
dc.identifier.issn0304-3835-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/176290-
dc.description.abstractTo elucidate the alterations of CDKN2 in hepatocarcinogenesis, we performed a loss of heterozygosity (LOH) study using eight polymorphic markers surrounding the CDKN2 gene and analyzed the homozygous deletions and mutations of the CDKN2 gene in 41 primary hepatocellular carcinomas (HCCs). Frequent LOH (27.8-44%) was found in the eight loci on chromosome 9p, however, no intragenic mutations of CDKN2 were observed by PCR-SSCP analysis. Homozygous deletions were detected in 25 of 41 HCCs (61%) by a comparative multiplex PCR. No expression of the CDKN2 protein was noted in five out of nine available HCCs by Western blot analysis. These results suggest that inactivation of the CDKN2 gene in HCC is a frequent event in which homozygous deletions are the most common mechanism of CDKN2 inactivation.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science Ireland-
dc.relation.isPartOfCANCER LETTERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular/genetics*-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHChromosomes, Human, Pair 9*-
dc.subject.MESHCyclin-Dependent Kinase Inhibitor p16/genetics*-
dc.subject.MESHGenes, Tumor Suppressor*-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/genetics*-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLoss of Heterozygosity*-
dc.subject.MESHMutation-
dc.titleHomozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학교실)-
dc.contributor.googleauthorZhe Piao-
dc.contributor.googleauthorChanil Park-
dc.contributor.googleauthorJin-Sung Lee-
dc.contributor.googleauthorChang Hyun Yang-
dc.contributor.googleauthorKang Yell Choi-
dc.contributor.googleauthorHoguen Kim-
dc.identifier.doi10.1016/s0304-3835(97)00403-5-
dc.contributor.localIdA01183-
dc.relation.journalcodeJ00448-
dc.identifier.eissn1872-7980-
dc.identifier.pmid9464511-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0304383597004035-
dc.contributor.alternativeNameKim, Hogeun-
dc.contributor.affiliatedAuthor김호근-
dc.citation.volume122-
dc.citation.number1~2-
dc.citation.startPage201-
dc.citation.endPage207-
dc.identifier.bibliographicCitationCANCER LETTERS, Vol.122(1~2) : 201-207, 1998-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.